Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy

Study ID
NCT02307500

Study type
Interventional

Study phase
Phase 2

Study status
Completed

Trial Acronym

RESOUND

Trial Summary

This is a single arm, single-stage, phase II trial to evaluate the activity of Regorafenib in patients with metastatic solid tumors (pancreatic cancer, ovarian cancer, melanoma, sarcoma, thymoma (type B2 - B3) and thymic carcinoma, who have progressed after standard therapy.

More informations

Trial Starting Date

Dec 31,2014

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit